Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space

The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.

Editorial use only - ARCADIA, CA - MAR 20: Horses break from the gate in an allowance race at Santa Anita Park on Mar 20, 2010 in Arcadia, CA — Mustang Bio announced data from the Phase I/II study of the anti-CD20 CAR-T therapy MB-106 in B-cell malignancies • Source: Shutterstock

The field of therapeutics for B-cell malignancies that target the CD20 antigen has become a crowded space, but Mustang Bio Inc. is developing an autologous chimeric antigen receptor T-cell (CAR-T) therapy that has a chance to stand out with early data showing a high response rate in patients, including those who previously received CAR-T cells.

Mustang announced data 25 April from a Phase I/II study of MB-106, a CD20-directed autologous CAR-T therapy that the company...